For the first time, inventors of a revolutionary sleep device have created a solution to improve oxygen levels for people who breathe through either their mouth or nose.
The O2Vent TTM developed by Australian medical device company Oventus, is a custom-made oral mouthguard that incorporates an airway that directs air to the back of the throat to increase airflow and bypass obstructions of the nose, tongue and soft palate.
No other sleep device on the market currently treats all three obstructions.
Oventus clinical director and Australian founder, Dr Chris Hart, said many sufferers of chronic nasal congestion experience major side effects including dry mouth, sore throat and daytime sleepiness.
“In addition to these unpleasant side effects, mouth breathing during sleep is linked to a lack of oxygen in the body and a higher incidence of snoring and Obstructive Sleep Apnoea (OSA),” said Dr Hart.
“OSA is a condition which causes the soft tissues of the throat to close or partially block the airway during sleep, preventing normal breathing and forcing sufferers to wake multiple times during the night.
“Studies have shown an increased severity of OSA in mouth breathing as compared with nasal breathing during sleep.
“This week is Sleep Awareness Week – the perfect time to focus on making sure you’re getting the sleep you need.
“A lack of sleep is strongly linked to workplace accidents and chronic health conditions such as high blood pressure, stroke, irregular heartbeats, heart attacks and diabetes.
“We understand the importance of this national awareness initiative and strongly encourage people to take a look at how much sleep they’re getting and to take action as there is treatment available.”
In many cases severe nasal obstruction may prevent sufferers from being able to use other oral appliances or the most common treatment available – Continuous Positive Airway Pressure (CPAP).
Oventus Medical will launch their O2Vent T today at the start of national Sleep Awareness Week. The device is included on the Australian Register of Therapeutic Goods (ARTG) in Australia.
A recent clinical study1 in Australia showed the device is successful in treating OSA and that snoring was either eliminated or significantly reduced in 100 per cent of patients. The study showed positive results in those people who had nasal obstructions and mainly breathed through their mouths, including when they were asleep.
“The recent clinical data strongly supports its superior performance and clearly demonstrates its effectiveness in treating a range of sleep disorders,” said Dr Hart.
“It also shows improved oxygen levels for patients and it means that a greater number of patients who are CPAP intolerant or mild to moderate sufferers of sleep apnoea now have an alternative treatment option available.”
1 Oventus clinical trial data on file